Cargando…
Nasogastric tube‐administered alectinib achieved long‐term survival in a crizotinib‐refractory nonsmall cell lung cancer patient with a poor performance status
Alectinib shows remarkable efficacy against anaplastic lymphoma kinase (ALK)‐positive nonsmall cell lung cancer (NSCLC), with minimal adverse effects. Therefore, alectinib may provide a survival benefit to ALK‐positive NSCLC patients with a poor performance status. If the medication cannot be taken...
Autores principales: | Kanai, Osamu, Kim, Young Hak, Nakatani, Koichi, Fujita, Kohei, Mio, Tadashi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5458002/ https://www.ncbi.nlm.nih.gov/pubmed/28588841 http://dx.doi.org/10.1002/ccr3.973 |
Ejemplares similares
-
Comparison of Alectinib/Crizotinib Data in First-Line Therapy in Patients with Anaplastic Lymphomakinase-Positive Nonsmall Cell Lung Carcinoma with Poor Prognostic Features for Alectinib
por: Katgı, Nuran, et al.
Publicado: (2023) -
Repetitive responses to nanoparticle albumin‐bound paclitaxel and carboplatin in malignant pleural mesothelioma
por: Kanai, Osamu, et al.
Publicado: (2016) -
Concurrence of nivolumab‐induced interstitial lung disease and cancer invasion
por: Kanai, Osamu, et al.
Publicado: (2017) -
Afebrile tension pyopneumothorax due to anaerobic bacteria: Fistula or gas production?
por: Kanai, Osamu, et al.
Publicado: (2021) -
No need to hesitate: immune‐related neutropenia and thrombocytopenia that improved by corticosteroids
por: Kanai, Osamu, et al.
Publicado: (2021)